Chemical structure of molecule Tepotinib (Merck KGaA MET kinase inhibitor)

oral MET kinase inhibitor

approved for clinical use in NSCLC

internal HTS and SBDD

Clinical Cancer Research

Merck KGaA

9.      The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.